Advanced Enzyme Technologies Limited

rs,

enzymes.com, www.advancedenzymes.com Where EI\IZYME is Life May 09, 2026 BSE Limited P. J. Towers, Dalal Street, Mumbai- 400 001 National Stock Exchange of India Limited Exchange Plaza, Plot No.

22%

ation | May 2026 3 Results Summary - Q4 FY26 (Consolidated) Y-o-Y Revenue (₹ mn) EBITDA (₹ mn) 22% 1,672 Q4 FY25 2,034 I Q4 FY26 39% 456 Q4 FY25 632 l Q4 FY26 Advanced enzy> 77705 : \

39%

4 FY26 (Consolidated) Y-o-Y Revenue (₹ mn) EBITDA (₹ mn) 22% 1,672 Q4 FY25 2,034 I Q4 FY26 39% 456 Q4 FY25 632 l Q4 FY26 Advanced enzy> 77705 : \ I V : PAT (₹ mn) 69% 267 Q4 FY25 45

69%

,034 I Q4 FY26 39% 456 Q4 FY25 632 l Q4 FY26 Advanced enzy> 77705 : \ I V : PAT (₹ mn) 69% 267 Q4 FY25 453 l Q4 FY26 Revenue grew by 22% on y-o-y basis to ₹ 2,034 million in Q4 FY26 f

₹ 2,034 million

: \ I V : PAT (₹ mn) 69% 267 Q4 FY25 453 l Q4 FY26 Revenue grew by 22% on y-o-y basis to ₹ 2,034 million in Q4 FY26 from ₹ 1,672 million in Q4 FY25 EBITDA grew by 39% to ₹ 632 million in Q4 FY26 as aga

₹ 1,672 million

7 Q4 FY25 453 l Q4 FY26 Revenue grew by 22% on y-o-y basis to ₹ 2,034 million in Q4 FY26 from ₹ 1,672 million in Q4 FY25 EBITDA grew by 39% to ₹ 632 million in Q4 FY26 as against ₹ 456 million in Q4 FY25 on

₹ 632 million

y-o-y basis to ₹ 2,034 million in Q4 FY26 from ₹ 1,672 million in Q4 FY25 EBITDA grew by 39% to ₹ 632 million in Q4 FY26 as against ₹ 456 million in Q4 FY25 on y-o-y basis PAT increased to ₹ 453 million in

₹ 456 million

4 FY26 from ₹ 1,672 million in Q4 FY25 EBITDA grew by 39% to ₹ 632 million in Q4 FY26 as against ₹ 456 million in Q4 FY25 on y-o-y basis PAT increased to ₹ 453 million in Q4 FY26 from ₹ 267 million in Q4 FY2

₹ 453 million

to ₹ 632 million in Q4 FY26 as against ₹ 456 million in Q4 FY25 on y-o-y basis PAT increased to ₹ 453 million in Q4 FY26 from ₹ 267 million in Q4 FY25, an uptick of 69% on y-o-y basis EBITDA margin and PAT

₹ 267 million

s against ₹ 456 million in Q4 FY25 on y-o-y basis PAT increased to ₹ 453 million in Q4 FY26 from ₹ 267 million in Q4 FY25, an uptick of 69% on y-o-y basis EBITDA margin and PAT margin during Q4 FY26 stands a

31%

n Q4 FY25, an uptick of 69% on y-o-y basis EBITDA margin and PAT margin during Q4 FY26 stands at 31% and 22% respectively Notes: 1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustme

18%

(Consolidated) Q-o-Q Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) Advanced enzy> 77705 : \ I V : 18% 1,719 Q3 FY26 2,034 I Q4 FY26 28% 494 Q3 FY26 632 l Q4 FY26 432 5% Q3 FY26 453 l Q

“And provision for sales return Earnings Presentation | May 2026 6 Human Nutrition ^Manced enzymes Wherp FN7YMFn Life (₹ in Million) (₹ in Million) +24% Q4 FY26 Q4 FY25 1,281 1,031 of Sales +15% FY26 4,674 FY25 4,053 of Sales”

“All the decimals are rounded off to their relevant nearest number Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Earnings Presentation | May 2026 7 Animal Nutrition ^Manced enzymes Wherp FN7YMFn Life (₹ in Million) (₹ in Million) +19% Q4 FY26 Q4 FY25 250 209 of Sales +25% FY26 FY25 946 760 of Sales”

“• The animal nutrition segment contributed around 12% during the quarter to the total revenue from operations • The animal nutrition segment contributed around 13% during the year to the total revenue from operations • This segment grew by 19% during the quarter from ₹ 209 million in Q4 FY25 to ₹ 250 million in Q4 FY26 whereas it grew by 2% on sequential basis • This segment grew by 25% on YTD basis to ₹ 946 million in FY26 as against ₹ 760 million in FY25 185 172 181 197 209 193 260 244”

“All the decimals are rounded off to their relevant nearest number Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Earnings Presentation | May 2026 8 250 I Industrial Bio-processing ^Manced enzymes Wherp FN7YMFn Life (₹ in Million) (₹ in Million) +17% Q4 FY26 Q4 FY25 324 278 of Sales +16% FY26 FY25 1,176 1,018 of Sales Q4 FY26: ₹276 mn Food 14% Q4 FY26: ₹47 mn Non-Food 2%”

“• The Industrial Bio-Processing segment contributed 16% during the quarter to the total revenue from operations • The Industrial Bio Processing segment contributed about 16% during the year to the total revenue from operations • This segment grew by 17% on y-o-y basis to ₹ 324 million in Q4 FY26 from ₹ 278 million in Q4 FY25, and on q-o-q basis it de-grew by 10% • In this segment, food business grew by 20% to ₹ 276 million on y-o-y basis during Q4 FY26 and de-grew by 11% on sequential basis.”

“All the decimals are rounded off to their relevant nearest number • This segment grew by 16% on YTD basis to ₹ 1,176 million in FY26 from ₹ 1,018 million in FY25 • In this segment, food business contributed 13% to the overall revenue and stood at ₹ 967 million while the Non Food business contributed 3% and stood at ₹ 209 million during the year.”

“The food business grew by 19% and the Non-food business remained flat on YTD basis 258 251 168 321 278 255 236 361 324 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Earnings Presentation | May 2026 9 Specialized Manufacturing ^Manced enzymes Wherp FN7YMFn Life (₹ in Million) (₹ in Million) +17% Q4 FY26 Q4 FY25 180 154 of Sales +23% FY26 FY25 662 539 of Sales”

“• This segment contributed about 9% during the quarter to the total revenue from operations • This segment contributed about 9% during the year to the total revenue from operations • This segment grew by 17% on y-o-y basis at ₹ 180 million in Q4 FY26, and on q-o-q basis it grew by 16% • This segment outperformed by 23% on YTD basis to ₹ 662 million in FY26 from ₹ 539 million in FY25 111 110 120 185 180 154 154 142 155”

Notes

8

Commentary

4

Contact

1

Notes

1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return Earnings Presentation | May 2026 4 Results Summary - Q4 FY26 (Consolidated) Q-o-Q Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) Advanced enzy> 77705 : \ I V : 18% 1,719 Q3 FY26 2,034 I Q4 FY26 28% 494 Q3 FY26 632 l Q4 FY26 432 5% Q3 FY26 453 l Q4 FY26 Revenue grew by 18% on q-o-q basis to ₹ 2,034 million in Q4 FY26 from ₹ 1,719 million in Q3 FY26 EBITDA grew by 28% to ₹ 632 million in Q4 FY26 as against ₹ 494 million in Q3 FY26 on sequential basis PAT increased to ₹ 453 million in Q4 FY26 from ₹ 432 million in Q3 FY26, a growth of 5% on q-o-q basis

Notes

1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return Earnings Presentation | May 2026 5 Results Summary - FY26 (Consolidated) YTD Revenue (₹ mn) EBITDA (₹ mn) 17% 6,369 FY25 7,458 l FY26 18% 1,944 FY25 2,291 l FY26 Advanced enzy> 77705 : \ I V : PAT (₹ mn) 30% 1,340 FY25 1,736 l FY26 Revenue grew by 17% on YTD basis to ₹ 7,458 million in FY26 from ₹ 6,369 million in FY25 EBITDA grew by 18% to ₹ 2,291 million in FY26 as against ₹ 1,944 million in FY25 on YTD basis PAT increased to ₹ 1,736 million in FY26 from ₹ 1,340 million in FY25, an uptick of 30% on YTD basis EBITDA margin and PAT margin during FY26 stands at 31% and 23% respectively

Notes

1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return Earnings Presentation | May 2026 6 Human Nutrition ^Manced enzymes Wherp FN7YMFn Life (₹ in Million) (₹ in Million) +24% Q4 FY26 Q4 FY25 1,281 1,031 of Sales +15% FY26 4,674 FY25 4,053 of Sales

Commentary

1,221 1,212 1,281 • The human nutrition segment contributed around 63% during the quarter to the total revenue from operations • The human nutrition segment contributed around 63% during the year to the total revenue from operations • This segment grew by 24% during the quarter from ₹ 1,031 million in Q4 FY25 to ₹ 1,281 million in Q4 FY26 and it grew by 33% on sequential basis • This segment grew by 15% during the year from ₹ 4,053 million in FY25 to ₹ 4,674 million in FY26 1,024 1,012 992 1,018 1,031 960

Notes

All the decimals are rounded off to their relevant nearest number Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Earnings Presentation | May 2026 7 Animal Nutrition ^Manced enzymes Wherp FN7YMFn Life (₹ in Million) (₹ in Million) +19% Q4 FY26 Q4 FY25 250 209 of Sales +25% FY26 FY25 946 760 of Sales

Commentary

• The animal nutrition segment contributed around 12% during the quarter to the total revenue from operations • The animal nutrition segment contributed around 13% during the year to the total revenue from operations • This segment grew by 19% during the quarter from ₹ 209 million in Q4 FY25 to ₹ 250 million in Q4 FY26 whereas it grew by 2% on sequential basis • This segment grew by 25% on YTD basis to ₹ 946 million in FY26 as against ₹ 760 million in FY25 185 172 181 197 209 193 260 244